Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Hepatocellular Carcinoma

Recruitment & Eligibility

Status: UNKNOWN

Sex: All

Target Recruitment: 179

Inclusion Criteria

Male and female patients >18 years of age
Histopathological diagnosis of hepatocellular carcinoma >3 months before entry (Arm A)
Received curative therapies, including surgery, ablation therapy or liver transplantation >3 months before entry (ArmA)
No evidence of hepatocellular carcinoma by imaging or histopathological studies at entry
Patients have never been treated with traditional interferon plus ribavirin or peginterferon plus ribavirin
Serologic evidence of chronic hepatitis C infection by an anti-HCV antibody test
Detectable serum HCV-RNA
Liver biopsy findings consistent with the diagnosis of chronic hepatitis C infection with or without compensated cirrhosis (Exception: hemophiliacs in whom biopsy is medically contra-indicated do not require biopsy.)
Compensated liver disease (Child-Pugh Grade A clinical classification)
Negative urine or blood pregnancy test (for women of childbearing potential) documented within the 24-hour period prior to the first dose of study drug
All fertile males and females receiving ribavirin must be using two forms of effective contraception during treatment and during the 6 months after treatment end

Exclusion Criteria

Women with ongoing pregnancy or breast feeding
Present therapy with any systemic anti-neoplastic or immunomodulatory treatment (including supraphysiologic doses of steroids and radiation) within 6 months prior to the first dose of study drug
Any investigational drug 6 weeks prior to the first dose of study drug
Co-infection with active hepatitis A, hepatitis B and/or human immunodeficiency virus (HIV)
History or other evidence of a medical condition associated with chronic liver disease other than HCV (e.g., hemochromatosis, autoimmune hepatitis, metabolic liver disease, alcoholic liver disease, toxin exposures)
Clinical evidence of hepatocellular carcinoma
History or other evidence of bleeding from esophageal varices or other conditions consistent with decompensated liver disease
Neutrophil count <1500 cells/mm3 or platelet count <90,000 cells/mm3 at screening
Serum creatinine level >1.5 times the upper limit of normal at screening
History of severe psychiatric disease, especially depression. Severe psychiatric disease is defined as treatment with an antidepressant medication or a major tranquilizer at therapeutic doses for major depression or psychosis, respectively, for at least 3 months at any previous time or any history of the following: a suicidal attempt, hospitalization for psychiatric disease, or a period of disability due to a psychiatric disease
History of a severe seizure disorder or current anticonvulsant use
History of immunologically mediated disease, chronic pulmonary disease associated with functional limitation, severe cardiac disease, major organ transplantation or other evidence of severe illness, or any other conditions which would make the patient, in the opinion of the investigator, unsuitable for the study
History of thyroid disease poorly controlled on prescribed medications, elevated thyroid stimulating hormone (TSH) concentrations with elevation of antibodies to thyroid peroxidase and any clinical manifestations of thyroid disease
Evidence of severe retinopathy (e.g. CMV retinitis, macula degeneration)
Evidence of drug abuse (including excessive alcohol consumption>40 g/day) within one year of study entry
Inability or unwillingness to provide informed consent or abide by the requirements of the study
Male partners of women who are pregnant
Hgb <11 g/dL in women or <12 g/dL in men at screening
Any patient with major thalassemia
Patients with documented or presumed coronary artery disease or cerebrovascular disease should not be enrolled if, in the judgment of the investigator, an acute decrease in hemoglobin by up to 4 g/dL (as may be seen with ribavirin therapy) would not be well-tolerated

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
CHC, HCC	peginterferon alpha-2a and ribavirin	100 naïve CHC patients concomitant with hepatocellular carcinoma without clinical evidence of HCC recurrence more than 3 months after curative treatments.
CHC, LC	peginterferon alpha-2a and ribavirin	100 naïve CHC patients without malignancy

Primary Outcome Measures

Name	Time	Method
Efficacy: sustained virological response (SVR), HCV RNA seronegative by PCR throughout 24-week off-treatment period.	1.5 years

Secondary Outcome Measures

Name	Time	Method
Rapid virologic response (RVR), HCV RNA seronegative by PCR at week 4.	1.5 years
Early virological response (EVR), by PCR-negative or at least 2 logs decline from baseline of serum HCV RNA at 12 weeks of treatment.	1.5 years
Safety: adverse event rate and profile.	1.5 years

Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Hepatocellular Carcinoma

Recruitment & Eligibility

Study & Design

Trial Locations

Instant Trial Alerts

Instant Trial Alerts